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Abstract
Hematopoietic stem cell transplantation is increasingly performed in several diseases; 
majority of them are hematologic malignancies. Hematopoietic stem cell transplantation 
is not an instant procedure; contrarily, its unique clinical and laboratorial consequences 
may take life‐long time. Blood product transfusion is an inevitable and critical component 
for the management. Hematopoietic stem cell transplant patients have different require‐
ments regarding blood products transfusion because of their immune status, long‐term 
cytopenias and especially HLA and ABO incompatibilities. Health‐care staff who take 
a part in the management of those patients should be aware of specific and specialized 
transfusion requirements.
Keywords: transfusion, hematopoietic stem cell transplantation, allogeneic, autologous, 
blood products
1. Introduction
1.1. Definition of hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) is the procedure that is transplantation of 
multipotent hematopoietic stem cells, which are derived from bone marrow, peripheral blood, 
or umbilical cord blood [1]. Autologous HSCT (Auto‐HSCT) is transplantation of stem cells, 
which are collected from the patient by apheresis and stored in a freezer for a while. Before re‐
transplantation of patients own stem cells, patient should be treated with high‐dose chemo‐
therapy (sometimes also with radiotherapy) in order to eradicate malignant cell population 
in the body. According to the intensity of chemo and radiotherapy to destroy bone marrow, 
this procedure may be partial or complete myeloablative. After myeloablation, bone marrow 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
is supposed to be free of malignant cells. Patient’s own stem cells then reinfused via his/her 
venous vascular access in order to locate bone marrow and maintain normal hematopoiesis. 
Patient have the risk of infection during leukopenia, but it is lower in auto‐ than allo‐HSCT 
because imunosuppression is milder in auto‐HSCT. Graft versus host disease (GVHD) is the 
condition in which white blood cells in the graft (donated blood product) recognize the host 
as a foreign particle and attack the host’s cells. GVHD is so rare but possible in auto‐HSCT 
although the host and the graft are genetically same. Donor in allo‐HSCT is another healthy 
person whose HLA (human leukocyte antigen) type is matched with the recipient. HLA gene 
complex encodes the major histocompatibility complex (MHC) cell‐surface proteins, which 
regulate immune system. Transplant reactions occur according to the compatibility of HLAs 
between donor and the recipient. Allogeneic transplant donors can be syngeneic (identical 
twin), HLA‐identical sibling, other family member or unrelated donor (from a volunteer). 
10/10 or 8/8 identical donor based on HLA high‐resolution typing for class I (HLA‐A, ‐B, ‐C) 
and II (HLA‐DRB1, ‐DQB1) is defined as well‐matched unrelated donor. A mismatched unre‐
lated donor means that at least one allele at HLA‐A, ‐B, ‐C or ‐DR are mismatched [2]. Related 
donors are relatives or siblings of the patient. Unrelated donors are available by national or 
Leukemias Lymphoid malignancies Other diseases
AML DLBCL Acquired SAA
ALL MCL Acquired AA/PNH
CML FL Constitutional SAA
• Fanconi anemia
• Dyskeratosis congenita
Myelofibrosis WM Germ cell tumors
MDS TCL Ewing’s sarcoma family of tumors
CLL Primary CTCL Multiple sclerosis
HL Systemic scleroderma
MM Systemic lupus erythematosus
AL Crohn’s disease
Rheumatoid arthritis
Vasculitis
Polymyositis‐dermatomyositis
Cytopenias
Note: AA = aplastic anemia, AML = acute myeloid leukemia, ALL = acute lymphoid leukemia, AL = amyloidosis, CML = 
chronic myeloid leukemia, CLL = chronic lymphocytic leukemia, CTCL = cutaneous T‐cell lymphoma, DLBCL = diffuse 
large B cell lymphoma, FL = folicular lymphoma, HL = hodgkin lymphoma, MCL = mantle cell lymphoma, MDS = 
myelodysplastic syndrome, MM = multiple myeloma, PNH = paroxismal nocturnal hemoglobinuria, SAA = severe 
aplastic anemia, TCL = T‐cell lymphoma, WM = waldenstrom macroglobulinemia.
Table 1. Indications of HSCT for adults.
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international bone marrow donor programs. Syngeneic donor means the monozygotic twin 
of the patient who is full HLA‐matched. Umbilical cord blood is an alternative source for 
hematopoietic stem cell. It is a kind of allo‐HSCT which is usually limited to children and the 
dose of the infused cells are very low [3]. Because of the similarity between allo‐HCST, we will 
not separately discuss transfusion in umbilical cord blood transplantation.
1.2. Indications for HSCT
HSCT is widely performed in hematologic malignancies but also indicated in other solid 
tumors, and non‐malignant diseases. Here are the lists of indications of HSCT for adults 
and children according to the sixth report from the European Society for Blood and Marrow 
Transplantation (EBMT) [2] (Tables 1 and 2). Because of the wide range of under‐investiga‐
tion indications, we only list diseases for which HSCT is standard of care, generally indicated 
in suitable patients or clinical option that can be carried after careful assessment of risks and 
benefits.
Hematological malignancies Non‐malignant disorders; solid tumors
AML Primary immunodeficiencies
ALL Thalassemia
CML Sickle cell disease (high risk)
NHL Aplastic anemia
HL Fanconi anemia
MDS Blackfan‐Diamond anemia
Chronic granulomatous disease
Kostman’s disease
MPS‐1H Hurler
MPS‐VI Maroteaux‐Lamy
Osteopetrosis
Autoimmune diseases
Germ cell tumor
Ewing’s sarcoma
Soft tissue sarcoma
Neuroblastoma
Wilm’s tumor
Brain tumors
AML = acute myeloid leukemia, ALL = acute lymphoid leukemia, CML = chronic myeloid leukemia, HL = Hodgkin 
lymphoma, NHL = non‐Hodgkin lymphoma, MDS = myelodysplastic syndrome, MPS = mucopolysaccharidosis.
Table 2. Indications of HSCT for children.
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2. Transfusion in transplantation
HSCT patients need transfusion of blood products before, during and after the transplanta‐
tion period. As a consequence of increase in the number of HSCTs, need for transfusions 
increased in the hospitals where transplantations are performed and also other health care 
centers that are involved in managing these patients. Transfusion in HSCT has unique fea‐
tures such as alloimmunization, ABO‐mismatched transplantations, infections and more that 
will be discussed in detail.
2.1. Before transplantation
Recipients of HSCT require special blood components such as leukocyte‐reduced, cytomega‐
lovirus (CMV) negative and γ‐irradiated blood components [4, 5].
2.1.1. Leukocyte‐reduced erythrocyte and platelet components
Leukocyte reduction from erythrocyte and platelet products prevents febrile, nonhemo‐
lytic transfusion reactions, alloimmunization to HLA antigens and transfusion‐transmitted 
cytomegalovirus (CMV) infections. HLA alloimmunization means formation of antibodies 
against non‐self HLA antigens. Anti‐HLA antibodies are inducible by multiple pregnancies 
and transfusion of blood products (especially if they are not leukocyte‐reduced). These anti‐
bodies are problematic in HSCT recipient because of the resistance or refractoriness to plate‐
let/erythrocyte transfusion and also cause cross‐match positivity against HLA antigens [6]. 
HLA crossmatch positive allo‐HSCT may result with primary graft rejection [6]. Leukocyte 
reduction filters are not completely effective, some leukocytes and membrane fragments are 
able to pass through them [5]. In spite of insufficiency to prevent HLA alloimmunization, 
transfusing only leukocyte‐reduced erythrocyte and platelet components to pretransplanta‐
tion patients is one of the few tools available to potentially reduce the risk of platelet transfu‐
sion refractoriness [7].
2.1.2. CMV infection
CMV serology status of both donor and the recipient is important components of transplan‐
tation. CMV transmission from blood products into immunocompromised patients such as 
transplant recipients can cause fatal infection. Current technologies in prevention of trans‐
mission include: provision of CMV‐seronegative blood components; postdonation leuko‐
cyte reduction filters; and pathogen inactivation, for example, photodynamic therapy with 
psoralens and UV or visible light [8]. The American Association of Blood Banks states that 
levels of less than 5 × 106 leukocytes per blood component may significantly reduce transfu‐
sion‐transmitted CMV infection [9]. There are also contrary results that support the use of 
CMV‐seronegative products to be superior to leukocyte reduction filters in preventing CMV 
transmission [10, 11]. The last survey of current practice for prevention of transfusion‐trans‐
mitted CMV in the United States reported wide variability in the use of leukoreduction ver‐
sus CMV‐seronegative products [12]. CMV serology should be tested for the donor and the 
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recipient. If the recipient is seropositive, the most common CMV infection is reactivation of 
latent infection; for this reason, using seronegative blood products has little importance. If 
HSCT is HLA‐matched sibling or autologous transplantation, CMV positivity of the patient 
may be overcome by preemptive antiviral treatment (ganciclovir, foscarnet) with or without 
high‐dose intravenous immunoglobulin [13–15]. CMV infection risk is the highest when CMV 
seropositive patients receive transplantations from unrelated, HLA‐mismatched, or sibling‐
matched (matched other than genotypic) donors and T lymphocyte‐depleted or cord blood 
allografts [7]. For this reason, most centers routinely administer anti‐CMV prophylactic ther‐
apy to HSCT recipients in whom immunocompetence is delayed (haploidentical, T‐lympho‐
cyte‐depleted, and cord blood transplantations) [7]. The risk for CMV infection is so low in 
seronegative HSCT recipient exposed to only seronegative blood products and CMV negative 
donor. Obtaining CMV negative blood products is not always easy, and urgent transfusions 
should not be delayed until seronegative products are available [7].
2.1.3. Transfusion‐related graft versus host disease and gamma irradiation
Transfusion‐related graft versus host disease (TR‐GVHD) is a complication of blood product 
transfusion, which contains donor T lymphocytes that engraft in susceptible immunosup‐
pressed host and trigger an immune response against it [16]. TR‐GVHD usually develops 
4–30 days after the blood transfusion. Viable donor lymphocytes attack recipient’s antigen‐
presenting tissues. The attack is manifested in skin, liver, gastrointestinal tract and bone 
marrow. Bone marrow involvement distinguishes TR‐GVHD from transplantation‐related 
disease. In HSCT, bone marrow is the nest for donor cells so privileged from the attack [17]. 
Usually donor lymphocytes are destroyed by the recipient’s immune system; however, this 
protection does not work in two conditions: immunodeficiency in the recipient and specific 
type of partial HLA matching between the donor and the recipient. Examples for immuno‐
deficient states are hematologic cancers, lymphoproliferative disorders, patients with solid 
tumors and rheumatologic diseases who are immunosuppressed because of chemotherapy 
or radiotherapy, Congenital immune deficiency, and AIDS [18–20]. Second setting for suscep‐
tibility to TR‐GVHD is that recipients of blood who are heterozygous for an HLA haplotype 
for which the donor is homozygous [21]. Donor lymphocytes are not detected as foreign 
particles by recipient, since the only HLA antigens seen by the host lymphocytes are shared 
by the recipient. But donor lymphocytes recognize the host’s tissues as foreign and initiate 
an immune attack which is named as TR‐GVHD. Blood products associated with TR‐GVHD 
are nonirradiated whole blood, packed red cells, platelets, granulocytes, and fresh and non‐
frozen plasma. TR‐GVHD is not associated with frozen, deglycerolized red cells, fresh frozen 
plasma, or cryoprecipitate. The early clinical features are fever, maculopapular skin rash, 
diarrhea and hepatitis occurring 1–2 weeks after transfusion. Later, bone marrow involve‐
ment produces severe hypoplasia with profound pancytopenia [22]. Diagnosis is generally 
made by the biopsy of the affected organs such as skin, gut, and liver, showing evidence 
of persistence of donor lymphocytes. In order to prove the donor lymphocytes in the host 
tissue, polymerase chain reaction in peripheral blood [23] or short tandem repeat analysis 
using peripheral blood and skin biopsies from affected and non‐affected sites in the patient, 
and peripheral blood samples from the implicated donors [24] can be used. The major way 
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for prevention from TR‐GVHD is gamma or X‐irradiation of blood components, by validated 
systems. The minimum dose achieved in the irradiation volume should be 25 Gy, not exceed‐
ing 50 Gy. Blood components that should be irradiated for at‐risk patients are all red cell, 
platelet, and granulocyte components except cryopreserved red cells after deglycerolization. 
There is no need to irradiate fresh frozen plasma, cryoprecipitate or fractionated plasma. Also 
all transfusions from first‐ or second‐degree relatives should be irradiated, even if the patient 
is immunocompetent. All recipients of allo‐HSCT must receive irradiated blood components 
from the time of initiation of conditioning chemoradiotherapy and should be continued while 
the patient keeps receiving GVHD prophylaxis. If chronic GVHD exist or immunusupres‐
sive treatment is continued, irradiated blood components should be given. Allo‐HSCT donors 
(peripheral blood or bone marrow) should be transfused with irradiated blood 7 days prior 
to or during the harvest. Auto‐HSCT patients should receive irradiated cellular blood compo‐
nents during and for 7 days before the harvest to prevent the collection of viable allogeneic 
T lymphocytes, which can potentially resist cryopreservation. Otherwise auto‐HSCT patients 
should receive irradiated cellular blood components from initiation of conditioning therapy 
until 3 months from transplantation (6 months if total body irradiation was used in condition‐
ing) [22].
2.2. Peritransplantation
The peritransplantation period begins with immunosuppressive preparation regimen, includ‐
ing stem cell infusion, and until engraftment. HSCT donor must be screened of blood group 
serology, HLA groups, CMV serology status, donor‐recipient size disparity, and donor health. 
Donor and recipient ABO/Rh (D) types are preferred to be compatible but if not, it does not 
exclude the HSCT donor volunteering. Nearly one‐half of all HSCT involve recipient‐donor 
ABO incompatibility [25].
2.2.1. ABO Incompatibility
Major ABO Mismatch: Donor’s erythrocytes are incompatible with recipient’s plasma. It occurs 
most frequently in group O patients who are receiving HSCT from group A, group B, or 
group AB donors and also when group A and group B recipients receive grafts from group AB 
donors. Erythrocyte content in the HSC graft should be minimal in order to prevent signifi‐
cant hemolysis after HSCT transfusion. Erythrocytes can be extracted from the donor’s bone 
marrow by Hetastarch separation, mononuclear cell concentration by machine, or through 
density gradient separation [26]. If a major ABO incompatibility exists, hematocrit should be 
less than 2% during apheresis collection [7].
Minor ABO Mismatch: Donor’s plasma is incompatible with recipient’s erythrocytes. ABO 
minor incompatibility may occur in such conditions: (1) if a patient of AB blood group 
receives HSCT from a non‐AB blood group donor, which contains anti‐A, anti‐B, or both; (2) 
if a patient from group A receives a B or an O HSCT, which contains anti‐A; or (3) if a group 
B patient receives an A or O transplantation, which contains anti‐B [25]. In order to mini‐
mize the risk plasma‐depleted HSCT products will be collected. The removed plasma volume 
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is proportional to the titer of the offending antibody(s) and the ratio of plasma‐to‐recipient 
erythrocyte volume [7].
2.2.2. Transfusion thresholds in peritransplatation period
Threshold for platelet transfusion is generally 10,000/μL in most transplantation centers 
[27, 28]. Nevertheless, patient’s clinical condition must be the basic determinant for transfu‐
sion requirements. Bleeding is common and multifactorial in HSCT patients such as mucositis, 
hemorrhagic cystitis, GVHD, veno‐occlusive disease (VOD), and diffuse alveolar hemor‐
rhage. If the patient has another factor for bleeding, platelet transfusion threshold must be 
personalised. In HSCT patients, platelet rise may be less efficient than other patient groups as 
a result of alloimmunization. HLA‐matched or crossmatched apheresis platelets are required 
to overcome alloimmunization.
Hemoglobin threshold for erythrocyte transfusion also varies for different clinical conditions. 
It can be summarized as follows [29]:
• Hemoglobin < 6 g/dL—transfusion recommended except in exceptional circumstances.
• Hemoglobin 6–7 g/dL—transfusion generally likely to be indicated.
• Hemoglobin 7–8 g/dL—transfusion may be appropriate in patients undergoing orthopedic 
surgery or cardiac surgery, and also for patients with underlying cardiovascular disease, 
after evaluation of the patient’s clinical needs.
• Hemoglobin 8–10 g/dL—in general, transfusion is not required, but some populations such 
as patients with symptomatic anemia, with active bleeding, suffering from acute coronary 
heart disease, and with hematological or oncological malignancies those having thrombo‐
cytopenia and at risk of bleeding may need erythrocyte transfusions.
• Hemoglobin > 10 g/dL—transfusion generally not indicated except in exceptional 
circumstances.
The impact of erythrocyte transfusions on outcome and the hemoglobin threshold in HSCT 
patients are not well understood. In a recent study, patients with a hematologic malignancy 
requiring HSCT were randomized to either a restrictive (hemoglobin threshold <7 g/dL) or 
liberal (hemoglobin threshold < 9 g/dL) erythrocyte transfusion strategies between Day‐0 and 
Day‐100. The use of a restrictive red blood cell (RBC) transfusion strategy is compared with 
a liberal strategy in patients undergoing HSCT as the HRQOL (health‐related quality of life) 
is similar and there are no appreciable differences in HSCT‐associated clinical outcomes [30].
2.2.3. Recommendations for ABO/Rh(D) matching
In HSCT, blood group matching is not required between donor and the recipient, but there are 
unique transfusion rules that exist. ABO incompatibility is classified as either major, minor, or 
bidirectional [25] (Table 3).
The clinical consequences and management of ABO incompatibilities are discussed below.
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Mismatch type ABO blood type Potential clinical consequence Etiology Potential interventions
Recipient Donor
Major 0 A, B • Acute hemolysis
• Delayed erythrocyte 
engraftment
• Delayed engraftment of granu‐
locyte and Platelets
• Pure red blood cell aplasia
• Transfusion of incompatible erythrocytes
• Patient anti‐donor isohemagglutinins
• Loss of immature stem cells from 
processing
• Loss of immature stem cells from pro‐
cessing with ABO antigens expressed on 
granulocytes and platelets
• Erythrocyte reduction of stem 
cell product
• Therapeutic plasma exchange 
in recipient to reduce 
isohemagglutinins before 
transplantation
• Promote donor erythro‐
poiesis via erythropoietin 
administration
AB
Major A AB
Major B AB
Minor A O • Acute hemolysis
• Delayed hemolysis second‐
ary to passenger lymphocyte 
syndrome
• Donor plasma with elevated isohem‐
agglutinin titers/small blood volume 
recipient
• Passenger lymphocytes 
producingisohemagglutinins
• Plasma reduction
• Continual clinical monitoring 
between days 5 and 15 for 
signs/symptoms of hemolysis 
and laboratory monitoring 
(LDH, bilirubin, complete 
blood count,DAT)
Minor B O
Minor AB O, A, B
Bidirectional A B • Combination of major and 
minor consequences
Combination of major and minor etiologies Combination of major and minor 
Bidirectional B A interventions
Bidirectional B A
Note: LDH = lactate dehydrogenase; DAT = direct antiglobulin test.
Table 3. Types of donor‐recipient ABO incompatibilities.
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2.3. After transplantation
ABO‐mismatched allo‐HSCTs have some complications such as immediate or delayed hemo‐
lytic reactions, delayed erythrocyte engraftment and red cell aplasia. Immediate immune 
hemolysis is usually after HPC transplantation infusion and is due to major ABO mismatch 
(because of the antibodies in the recipient), whereas delayed hemolysis is a consequence of 
minor ABO‐mismatch (because of donor blood group antibodies) [7]. Several clinical con‐
ditions that can mimic immune hemolysis include veno‐occlusive disease, GVHD, and 
thrombotic thrombocytopenic purpura. Direct antiglobulin positivity is highly suspicious 
for transplant‐related immune hemolysis. Table 4 demonstrates an overview to hemolysis in 
patients after HSCT [7].
2.3.1. Passenger lymphocyte syndrome
Passenger lymphocyte syndrome (PLS) occurs when transplanted B lymphocytes produce 
incompatible blood group antibodies after transplantation [31]. Hemolysis due to PLS may be 
delayed by 5–15 days after transplantation but is rare after 6–8 weeks [32, 33]. PLS includes 
ABO incompatibility; additionally, incompatibility in the Rh, Kell, Duffy, or Kidd blood group 
systems has been reported [34–37]. It is wise to expect higher PLS in peripheral HSCT than 
bone marrow HSCT because of the higher lymphocyte content in peripheral blood but reports 
regarding this are mostly anecdotal [7]. Other risk factors for PLS are the use of cyclosporine 
alone in the absence of an antiproliferative agent, such as methotrexate, for posttransplan‐
tation GVHD prophylaxis [38, 32], and the use of a reduced‐intensity preparative regimen. 
After 5–15 days, hemolysis limits itself as the incompatible erythrocytes are eliminated and 
switched by donor or transfused erythrocytes. “Bystander” immune hemolysis is the term, 
when hemolysis is more extensive than expected from patient’s erythrocytes alone, attributed 
to hemolysis of transfused compatible erythrocytes [38]. Plasma reduction does not diminish 
the B lymphocyte content of HSC material and, for this reason, does not affect the incidence 
of PLS. Rituximab may be used in PLS prevention [39]. Pretransplantation red cell exchange 
procedures to reduce the volume of donor incompatible erythrocytes in the recipient before 
infusion are found to be ineffective and associated with a relatively large fraction of residual 
recipient red cells [40].
The major complications of major ABO‐incompatible transplantation include delayed red cell 
engraftment and pure red cell aplasia (PRCA). Major ABO incompatibilities may cause delay 
in RBC engraftment. The diagnosis of PRCA is established if reticulocytopenia persists for 
more than 60 days and erythrocyte precursors are absent in the bone marrow aspirate. In addi‐
tion, an inverse correlation between ABO hemagglutinin titers and reticulocyte counts exists. 
In some major ABO incompatible allo‐HSCTs, donor hematopoietic stem cells’ conversion and 
RBC production are inhibited by isohemagglutinins produced by recipient plasma [41]. The 
primary pathology is disruption of normal bone marrow maturation by the recipient isohem‐
agglutinins at the colony‐forming‐units‐ertyhroid stage [42]. Time for recovery of erythropoi‐
esis depends on the pretransplantation titer of antidonor isohemagglutinins, quantity of target 
antigen available, rate of clearance of isohemagglutinins, presence of GVHD, transplantation‐
conditioning regimen, and the native recipient erythropoietic function [43, 44]. Resolution of 
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Diagnosis Pathophysiology Serologic findings
HSC graft‐related immune hemolysis
Major ABO incompatibility between 
HSC donor and recipient
Hemolysis of transfused 
erythrocytes, delay in erythrocyte 
engraftment
DAT positive for C3d, IgG or both; 
anti‐A and/or anti‐B present in eluate
Minor ABO incompatibility between 
HSC donor and recipient
Hemolysis of patient’s erythrocytes 
caused by transfused donor’s plasma 
or by passenger lymphocyte‐derived 
isohemagglutinins
DAT positive for C3d, IgG or both 
anti‐A and/or anti‐B present in eluate
Major incompatibility: other blood 
group antigens
Hemolysis of transfused donor’s 
erythrocytes
DAT positive for C3d, IgG or both; 
antibody to non‐ABO red blood cell 
antigen(s) identified in eluate and 
patient plasma
Minor incompatibility: other blood 
group antigens
Hemolysis of patient’s erythrocytes 
caused by alloantibodies in 
transfused donor plasma or by 
passenger lymphocyte‐derived 
alloantibodies
DAT positive for C3d, IgG, or both: 
antibody to non‐ABO red blood cell 
antigen(s) identified in eluate and 
patient plasma
Transfusion‐related immune hemolysis
Transfusion of erythrocytes 
incompatible with donor or patient
Hemolysis of transfused erythrocytes 
caused by patient’s native or graft‐
derived antibodies
DAT positive for C3d, IgG or both: 
anti‐A and/or anti‐B or antibody to 
other RBC antigen identified in eluate 
and patient plasma
Transfusion of plasma incompatible 
with donor or patient
Hemolysis of patient and/or donor 
erythrocytes
DAT positive for C3d, IgG or both; 
anti‐A and/or anti‐B or antibody to 
other RBC antigen identified in eluate 
and patient plasma
Other causes of immune hemolysis
Autoimmune hemolytic anemia Hemolysis and serologic 
incompatibility of (all) crossmatched 
donor erythrocytes
DAT positive for C3d, IgG or both; 
panagglutinin present in eluate and 
patient plasma
Drug‐induced hemolytic anemia Autoantibody formation induced by 
drug, hapten mechanism, or drug 
modification of erythrocyte membrane
DAT positive for C3d, IgG or both; 
eluate may react with drug‐treated 
erythrocytes
Nonimmune hemolysis
TTP Microangiopathic hemolytic anemia DAT and antibody screen negative
Cryopreserved stem cell products 
infusion
Nonimmune hemolysis may be 
observed during infusion of DMSO‐
cryopreserved HSC preparations
DAT negative
Clostridium perfringens sepsis C perfringens‐produced hemolysin 
toxins cause nonimmune 
intravascular hemolysis
DAT negative
Note: HSC = hematopoietic stem cell, DAT = direct antiglobulin test, C3D = complement factor 3D, DMSO = dimethyl 
sulfoxide, IgG = immunoglobulin G, RBC = red blood cell, TTP = thrombotic thrombocytopenic purpura.
Table 4. Differential diagnosis of hemolysis in HSCT patients.
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PRA usually takes a few weeks or months but rarely continues for 5 years [45]. Management of 
PRA includes tapering immunosuppression, using erythropoietin, steroids, plasma exchange, 
rituximab, and donor lymphocyte infusions [46–48].
2.4. Post‐engraftment period
There are some clinical conditions specific to post‐engraftment of stem cells, which may 
increase the requirement for blood products.
2.4.1. Graft‐versus host disease
In acute GVHD cytopenias of 1–3 cell lines and an immune‐based hemolytic anemia may 
occur; also, gastrointestinal GVHD may cause bleeding because of ulcers in gastrointestinal 
system, and severe liver GVHD may also develop the clotting disturbances [49]. Blood prod‐
uct support during GVHD is essential.
2.4.2. Hemorrhagic cystitis
Hemorrhagic cystitis is a toxicity related with cyclophosphamide; however, several viral etiolo‐
gies, including adenovirus and BK virus, have been reported [50]. HSCT patients with hemor‐
rhagic cystitis may require RBC replacement proportional to its loss and platelet transfusion if the 
patient is thrombocytopenic. Tranexamic  acid should be avoided because of possible clothing 
within the ureters. Bladder irrigation and platelet transfusion are the mainstay of the treatment.
2.4.3. Hepatic veno‐occlusive disease
Hepatic veno‐occlusive disease (VOD), also known as sinusoidal obstruction syndrome, is 
a major complication of HSCT and carries a high mortality risk. Many different risk factors 
for VOD have been described, including platelet transfusions containing ABO‐incompatible 
plasma [51]. Incompatible isoagglutinins to ABO blood‐group antigens on hepatic sinusoi‐
dal endothelial cells may cause toxic injury initiating a sequence of biological events that 
may lead to circulatory compromise of centrilobular hepatocytes, fibrosis, and obstruction of 
blood flow, resulting in VOD [7]. It is wise to think that all platelet transfusions after HSCT 
should be ABO‐compatible with both donor and recipient blood types. In VOD, the need for 
platelet transfusion is increased as a result of activated coagulation and portal hypertension‐
related thrombocytopenia.
2.4.4. Donor lymphocyte infusion
Donor lymphocyte infusion (DLI) is one of the strategies for managing relapsed hematologic 
malignancy after HSCT. This procedure is the infusion of lymphocytes from the original stem 
cell donor after the transplant to augment an antitumor immune response or to be sure that 
the donor HSCs remain engrafted. Aim is to initiate the process called the graft‐versus‐tumor 
effect. T cells of donor are supposed to attack residual cancer cells.
Transfusion in Transplantation
http://dx.doi.org/10.5772/intechopen.69260
101
2.4.5. Granulocyte transfusion
Granulocyte transfusion is not routine procedure, but larger doses of granulocytes collec‐
tion became possible after the discovery and availability of recombinant granulocyte colony‐
stimulating factor (G‐CSF) increased the interest for the issue [52]. It is possible to collect 
5–10 × 1010 granulocytes at once [53–55]. Some authors recommend granulocyte transfusion in 
patients meet that criterion regardless of the cause of neutropenia [56]:
• Absolute neutrophil count <500 cells/μL, except in the case of chronic granulomatous 
disease.
• Evidence of bacterial or fungal infection (i.e., clinical symptoms of infection, positive 
cultures, pathological diagnosis of infection from biopsies, radiographic evidence of 
pneumonia).
• Unresponsiveness to antimicrobial treatment for at least 48 hours (except in extreme cir‐
cumstances with life‐threatening infection)
Chemotherapy and HSCT are the most common indications for granulocyte transfusion even 
though their use is rare in daily practice. Family members and community donors both can 
donate granulocytes; however, donor must fulfill some criterion. Donors must be ABO and 
Rh‐matched to the recipient, negative for all blood transfusion‐associated infectious disease 
markers within 30 days of granulocyte donation, having good vascular access, and not be 
pregnant and having hemoglobinopathy. G‐CSF (300 mcg subcutaneously) and dexametha‐
sone (8 mg orally) are administered on the day prior to each collection [54]. Granulocyte har‐
vesting by apheresis is performed by removing granulocytes and returning erythrocytes and 
plasma to the donor. Adverse reactions associated with granulocyte transfusion are pulmo‐
nary adverse reactions [57], transfusion‐associated GVHD [58], alloimmunization [59], and 
infections [60], especially CMV [61].
2.4.6. Erythrocyte chimerism
Allo‐HSCT patients should be assessed with chimerism studies in order to detect the genotypic 
origin of posttransplant hematopoiesis. This study serves to define engraftment, graft failure, 
and relapse. Complete chimerism means hematopoiesis is entirely from the donor; mixed chi‐
merism is the condition that a variable ratio of donor‐ to recipient‐derived cells, and engraft‐
ment failure means cells are all from the recipient. Blood group chimerism is an important 
issue in allo‐HSCT patients. According to ABO matching, varied incidences of ABO‐grouping 
discrepancies or mixed field‐agglutination reactions have been reported [7]. Antierythrocyte 
antibodies are measured to document erythrocyte chimerism, once the patient’s blood becomes 
full‐donor chimera, recipient‐derived antierythrocyte antibodies disappear. Then, blood prod‐
ucts consistent with donor ABO typing should be used. After establishing full donor engraft‐
ment, the onset of mixed erythrocyte chimerism (circulating erythrocytes typing with mixed 
field‐donor recipient ABO groups) may be signaling for the relapse and/or graft failure [62].
Transfusion‐support recommendations for ABO incompatible HSCT are summarized in Table 5 
[25].
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Recipient Donor Phase 1 Phase 2 Phase 3
All products RBC’s Platelets Plasma RBC’s Platelets Plasma
1st Choice 2nd Choices 1st Choice 2nd Choices 1st Choice 2nd Choices 1st Choice 2nd Choices
O A Recipient O A AB, B, O A AB Donor A AB, B, O A AB
O B Recipient O B AB, A, O B AB Donor B AB, A, O B AB
O AB Recipient O AB A, B, O AB NA Donor AB A, B, O AB NA
A AB Recipient A AB A, B, O AB NA Donor AB A, B, O AB NA
B AB Recipient B AB B, A, O AB NA Donor AB B, A, O AB NA
A O Recipient O A AB, B, O A AB Donor A AB, B, O A AB
B O Recipient O B AB, A, O B AB Donor B AB, A, O B AB
AB O Recipient O AB A, B, O AB NA Donor AB A, B, O AB NA
AB A Recipient A AB A, B, O AB NA Donor AB A, B, O AB NA
AB B Recipient B AB B, A, O AB NA Donor AB B, A, O AB NA
A B Recipient O AB B, A, O AB NA Donor AB B, A, O AB NA
B A Recipient O AB O, A, B AB NA Donor AB A, B, O AB NA
Note: NA = not applicable; Phase 1 = time period between diagnosis and transplantation; Phase 2 = time period between transplantation and RBC engraftment; Phase 3 = 
engraftment established, as indicated by direct antiglobulin testing being negative, along with two consecutive separate samples with the forward and reverse typing 
showing donor ABO status.
Table 5. Transfusion support recommendations for ABO incompatible HSCT. Transfusion in Transplantation
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Autologous and allogeneic HSCT are associated with pancytopenia in the pre‐, peri‐, and 
posttransplant period. Blood product transfusion is an inevitable and critical component for 
the patient management. HSCT patients have special requirements regarding blood products 
transfusion. Transfusion services, hospitals, physicians, and other health care staff who take 
care of transplant patients should be aware of that those patients have specific and specialized 
transfusion requirements.
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